Nature Search

Establishment of an African green monkey model for COVID-19 and protection against re-infection

Geisbert and colleagues report that African green monkeys infected with the SARS-CoV-2 virus develop disease symptoms that closely resemble those seen in infected humans, making this animal model a useful surrogate to investigate immune responses to coronavirus infection.

Courtney Woolsey
Viktoriya Borisevich
Robert W. Cross
Research24 Nov 2020
Nature Immunology

Volume: 22, P: 86-98
Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment

During an ongoing Ebola virus outbreak, infection before onset of protective immunity from vaccination is a possible scenario. Here the authors show in non-human primates that vaccination shortly before treatment with a monoclonal antibody does not negatively affect effectiveness of the antibody therapy.

Robert W. Cross
Zachary A. Bornholdt
Thomas W. Geisbert
ResearchOpen Access27 Jul 2020
Nature Communications

Volume: 11, P: 1-8
Remdesivir, mAb114, REGN-EB3, and ZMapp partially rescue nonhuman primates infected with a low passage Kikwit variant of Ebola virus

Prasad et al. assess four therapeutics in preventing lethal disease in an established nonhuman primate model of Ebola virus infection. They find that each therapy results in ~ 40% survival, suggesting the use of alternative strategies, such as combining therapeutics to combat Ebola.

Abhishek N. Prasad
Courtney Woolsey
Thomas W. Geisbert
ResearchOpen Access23 Apr 2025
Nature Communications

Volume: 16, P: 1-13
Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates

Ebola-virus-targeting short interfering RNAs (siRNAs) encapsulated in lipid nanoparticles are adapted to the current outbreak strain of the virus, and the siRNA cocktail is shown to protect nonhuman primates fully when administered 3 days after challenge with the current West African Ebola virus isolate; upon viral sequence data availability, the drug can be adapted to the new virus and produced in as little as 8 weeks.

Emily P. Thi
Chad E. Mire
Thomas W. Geisbert
Research22 Apr 2015
Nature

Volume: 521, P: 362-365
Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA

Treatment with lipid nanoparticles encapsulating siRNAs targeting the viral VP35 gene are able to rescue rhesus macaques infected with a lethal dose of Sudan ebolavirus.

Emily P. Thi
Amy C. H. Lee
Chad E. Mire
Research22 Aug 2016
Nature Microbiology

Volume: 1, P: 1-10
Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever

Thomas Geisbert and colleagues show that a cocktail of monoclonal antibodies protects cynomolgus monkeys from lethal Lassa fever virus infection, including when administration is delayed by more than a week after viral challenge.

Chad E Mire
Robert W Cross
Thomas W Geisbert
Research04 Sept 2017
Nature Medicine

Volume: 23, P: 1146-1149
Combination therapy protects macaques against advanced Marburg virus disease

Extending the therapeutic window for acute viral infections could save lives. Here, the authors show that combination treatment with a human monoclonal antibody and remdesivir initiated at 6 days post infection with Marburg virus provides 80% protection in non-human primates.

Robert W. Cross
Zachary A. Bornholdt
Thomas W. Geisbert
ResearchOpen Access25 Mar 2021
Nature Communications

Volume: 12, P: 1-10
Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus

Two second-generation attenuated Ebola virus vaccines based on recombinant vesicular stomatitis virus protect macaques against infection with a recent Ebola virus isolate from Guinea.

Chad E. Mire
Demetrius Matassov
Thomas W. Geisbert
Research08 Apr 2015
Nature

Volume: 520, P: 688-691
Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits

Lassa virus can cause haemorrhagic fever for which no specific treatment currently exists. Here the authors have cloned 113 monoclonal antibodies from the survivors of Lassa infection and show that the majority of neutralizing antibodies target a complex of GP1 and GP2 viral proteins.

James E. Robinson
Kathryn M. Hastie
Robert F. Garry
ResearchOpen Access10 May 2016
Nature Communications

Volume: 7, P: 1-14
CD8⁺ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates

Vaccines that protect nonhuman primates from lethal Ebola virus infection have been developed, but their protective mechanisms have not been clearly delineated. Nancy Sullivan et al. now report that the protective efficacy of a recombinant Ad5-based Ebola virus vaccine relies primarily on CD8⁺ T cells rather than on antibodies. The findings suggest that clinical development of T cell–based vaccines against Ebola virus is warranted.

Nancy J Sullivan
Lisa Hensley
Gary J Nabel
Research21 Aug 2011
Nature Medicine

Volume: 17, P: 1128-1131
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses

Steven M Jones
Heinz Feldmann
Thomas W Geisbert
Research05 Jun 2005
Nature Medicine

Volume: 11, P: 786-790
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates

Nancy J. Sullivan
Thomas W. Geisbert
Gary J. Nabel
Research07 Aug 2003
Nature

Volume: 424, P: 681-684
The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset

David Safronetz
Kyle Rosenke
Brian B. Gowen
ResearchOpen Access12 Oct 2015
Scientific Reports

Volume: 5, P: 1-11
Pathogenic Differences between Nipah Virus Bangladesh and Malaysia Strains in Primates: Implications for Antibody Therapy

Chad E. Mire
Benjamin A. Satterfield
Thomas W. Geisbert
ResearchOpen Access03 Aug 2016
Scientific Reports

Volume: 6, P: 1-16
Natural history of nonhuman primates after conjunctival exposure to Ebola virus

Robert W. Cross
Abhishek N. Prasad
Thomas W. Geisbert
ResearchOpen Access13 Mar 2023
Scientific Reports

Volume: 13, P: 1-12
A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus

Thomas W. Geisbert
Kathryn Bobb
Antony S. Dimitrov
ResearchOpen Access08 Feb 2021
npj Vaccines

Volume: 6, P: 1-12
Immune correlates of postexposure vaccine protection against Marburg virus

Courtney Woolsey
Allen Jankeel
Thomas W. Geisbert
ResearchOpen Access20 Feb 2020
Scientific Reports

Volume: 10, P: 1-18
Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants

Krista Versteeg
Andrea R. Menicucci
Thomas W. Geisbert
ResearchOpen Access29 Aug 2017
Scientific Reports

Volume: 7, P: 1-16
Author Correction: Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants

Krista Versteeg
Andrea R. Menicucci
Thomas W. Geisbert
Amendments and CorrectionsOpen Access08 May 2019
Scientific Reports

Volume: 9, P: 1-4

Search

Establishment of an African green monkey model for COVID-19 and protection against re-infection

Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment

Remdesivir, mAb114, REGN-EB3, and ZMapp partially rescue nonhuman primates infected with a low passage Kikwit variant of Ebola virus

Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates

Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA

Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever

Combination therapy protects macaques against advanced Marburg virus disease

Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus

Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits

CD8⁺ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates

Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses

Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates

The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset

Pathogenic Differences between Nipah Virus Bangladesh and Malaysia Strains in Primates: Implications for Antibody Therapy

Natural history of nonhuman primates after conjunctival exposure to Ebola virus

A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus

Immune correlates of postexposure vaccine protection against Marburg virus

Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants

Author Correction: Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants

Search

Quick links

Search

Filter By:

Search

Quick links